AT132 has prompted more safety concerns, this time at a lower dose than before.
If the first quarter was quiet for takeovers the second saw M&A grind to a halt. What can the matter be?
One-year data look encouraging, but etranadez will now not be filed until 2022.
Covid-19 vaccine developers stand out as global drug stocks tread water in the first quarter.
The failure of Roche and Ionis’s late-stage candidate tominersen casts doubt on Wave’s approach, too.
The Japanese group pays $120m for Anima’s preclinical small-molecule approach.
A rollercoaster year for biopharma ended with investors firmly deciding that the pandemic was an opportunity, not a threat.